Antibiotic Stewardship Certificate for Nurses

This activity is expired.

Antibiotic resistance (ABR) is considered to be a silent pandemic poised to reverse a century of medical progress, rendering antibiotics ineffective in treating even the most common infectious diseases. According to the Centers for Disease Control and Prevention more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. Globally, it is estimated that 700,000 people die from drug-resistant infections yearly. Unless major actions are taken this number is projected to rise to 10 million yearly by 2050 at an economic impact of 100 trillion dollars per year.

Dedicated prevention and infection control efforts in the U.S. reduced deaths from anti-biotic-resistant infections by 18% overall and by nearly 30% in hospitals. However, the number of people facing antibiotic resistance is still too high. More action is needed to fully protect people. Improving the way antibiotics are prescribed and used or “antibiotic stewardship,” is critical to effectively treat infections, protect patients from harms caused by unnecessary antibiotic use, and combat antibiotic resistance.

Aiming to combat the threat of antibiotic resistance to patient safety and public health, the Jefferson College of Nursing developed this educational offering on antibiotic stewardship specifically for nurses. The course will help nurses participate and lead antibiotic stewardship nursing practices and deliver effective and consistent messages to patients and the public about antibiotic use and antibiotic resistance. 

1. Discuss antibiotic resistance and the impact on patients, populations and society.
2. Describe core elements of antibiotic stewardship programs.
3. Examine key nursing antibiotic stewardship practices.
4. Discuss fundamental microbiology, selected bacterial infections and antibiotic use.
5. Identify improvement methods and tools that can be used to implement nursing antibiotic stewardship practices.

*Subject to verification. Please use institutional email address when creating profile.

Successful Completion

•  Four online asynchronous sequential self-paced learning modules to be complete within six weeks of registration. 
• Complete the online evaluation. 

Planning Committee
None of the planners have any financial relationships to declare.

• Mary Lou Manning PhD, CRNP, CIC, FAAN-Activity Director
• Catherine Harris, PhD, MBA, AGACNP, ANP, FNP-BC-Content Reviewer
• Eleanor Fitzpatrick RN, DNP, AG-CNS, ACNP, CCRN, CCCTM-Content Reviewer
• Monika Pogorzelska-Maziarz PhD, MPH, CIC, FAPIC
• Cindy M. Hou DO, MA, MBA, FACOI, FACP
• Nikuny Vyas, PharmD, BCPS
• Eileen Carter, PhD, RN
• Elizabeth Monsees, PhD, MBA, RN, CIC, FAPIC
• Marianne Kraemer RN MPA, Ed.M, CENP, CCRN-K

Course Faculty
None of the course authors have any financial relationships to declare.

• Mary Lou Manning, PhD, CRNP, CIC, FAPIC, FAAN
• Eileen Carter, PhD, RN
• Cindy Hou, DO, MBA, FACOI, FACP, FIDSA
• Elizabeth Monsees, PhD, MBA, RN, CIC, FAPIC 
• Nikunj Vyas, PharmD, BCPS
  

Mitigation of Relevant Financial Relationships

Thomas Jefferson University adheres to the Standards for Integrity and Independence in Accredited Continuing Education and the policies that supplement the Standards.

All planners, faculty, and others in control of educational content are required to disclose any relevant financial relationships with ACCME defined ineligible companies within the past 24 months. Any conflicts of interests have been mitigated prior to this educational activity. Such disclosures will be available prior to the start of the activity. Jefferson conflict of interest mitigation process may result in changes to the program agenda.

Off-Label/Investigational Use
All faculty/presenters/authors at Thomas Jefferson University sponsored events are required to disclose whether or not their content contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. Product(s) is/are not included in the labeling approved by the U.S. FDA for the treatment of disease(s).

Content Disclaimer
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices or Thomas Jefferson University.

It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

This educational activity received no commercial or in-kind support.